Legend Biotech 株価情報 (NASDAQ: LEGN)

Legend Biotech (NASDAQ:LEGN) 株価情報

Legend Biotech

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

News

Movers

ACLS

AGIO

HALO

IRTC

LBTYB

LEGN

NEOG

NUVL

NVAX

NVDA

SMAR

TWST

VRNT

これらの中型株は直近1週間で最も好調のパフォーマンスを示しました。あなたのポートフォリオには入っていますか？

直近1週間高パフォーマンスを示したのは、中型株

Legend Biotech Corporation - American Depositary Shares

Legend Biotech Corp

Offerings

Wayfair  Intends To Offer $700M Of Senior Secured Notes Due 2030 In Private Offering

HC Wainwright &amp; Co. analyst Robert Burns maintains Nuvation Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>) with a Buy and lowers the price target from $11 to $10.

Price Target

Analyst Ratings

NUVB

HC Wainwright & Co. Maintains Buy on Nuvation Bio, Lowers Price Target to $10

Tesla Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares declined over 3% in pre-market trade on Monday amid lower deliveries and a decline in brand image over Elon Musk's involvement in politics and Department of Government Efficiency (DOGE).
What Happened: Elon Musk's net worth has declined by over $52 billion this year, and over a $100 billion year-to-date decline, as per the Bloomberg Billionaires Index.
Tesla stock has lost over a third of its value since the start of the year, pushing the company's market capitalization below the $1 trillion mark for the first time since November.
In early 2025, Tesla&#8217;s sales in California dropped by 12%, raising questions about the impact of Musk&#8217;s political support for Donald Trump on<a href="https://www.benzinga.com/trading-ideas/25/02/43447273/tesla-sales-drop-12-in-california-is-elon-musks-support-for-donald-trump-hurting-ev-sales"> EV sales</a>. Additionally,<a href="https://www.benzinga.com/25/01/43152718/tesla-to-have-a-choppy-first-half-owing-to-new-ev-policies-deliveries-and-margins-however-this-analyst-expect-over-20-upside-from-current-level-with-a-500-target-price"> analysts</a> predicted a &#8220;choppy&#8221; first half for Tesla due to new EV policies and uncertainties in deliveries.
Tesla&#8217;s California sales hit a four-year low, with<a href="https://www.benzinga.com/25/02/43765071/teslas-california-sales-hit-four-year-low-amid-political-concerns-researcher-says-left-leaning-customers-are-turning-away-from-ev-giant"> researchers</a> attributing this to Musk&#8217;s political actions.
Price Action: Tesla stock declined more than 3% during pre-market hours, after closing 0.3% down on Friday. Tesla shares have declined by nearly 35% year-to-date, according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro data</a>.
Benzinga Pro data shows analysts have a consensus "Buy" rating on the TSLA stock. Based on the three most recent analyst ratings from Wedbush, Baird and Bank of America Securities, the average price target of $433 implies an upside of 68%.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<a href="https://www.benzinga.com/25/03/44215061/tesla-bull-says-ev-giants-q1-delivery-shortfall-is-not-due-to-elon-musks-political-comments-and-doge-republicans-are-likely-thrilled">Tesla Bull Says EV Giant&#8217;s Q1 Delivery Shortfall Is Not Due To Elon Musk&#8217;s Political Comments And DOGE: &#8216;Republicans Are Likely Thrilled&#8217;</a>
Photo courtesy: Shutterstock

Equities

Markets

Tech

TSLA

TSLA Stock Drops Over 3% In Monday Pre-Market Amid Lower Deliveries, Declining Brand Image

Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) reported quarterly sales of $7.000 million which beat the analyst consensus estimate of $2.000 million by 250.00 percent.

Earnings

Earnings Beats

PRLD

Prelude Therapeutics FY Sales $7.000M Beat $2.000M Estimate

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) with a Buy and maintains $10 price target.

Reiteration

RAPT

HC Wainwright & Co. Reiterates Buy on RAPT Therapeutics, Maintains $10 Price Target

Diversified Energy Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEC#NYSE">DEC</a>), FuelCell Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>), and TESIAC disclosed a strategic partnership to meet the growing <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44213155/diversified-energy-fuelcell-energy-and-tesiac-collaborate-to-form-an-acquisition-and-development-c" rel="noreferrer noopener">energy demands of data centers</a>.
The collaboration plans to supply up to 360 megawatts of electricity across three locations in Virginia, West Virginia, and Kentucky.
The partnership will form an Acquisition and Development Company (ADC) to deliver reliable, cost-efficient, net-zero power from natural gas and captured coal mine methane (CMM) for data centers.
Leveraging local gas production, fuel cell technology, and infrastructure financing, the collaboration aims to create a scalable, sustainable energy solution to meet growing data center demands.
This partnership aims to develop a decentralized, high-performance, and sustainable energy solution to support the growing power demands of AI and high-performance GPU-driven data centers.
Utilizing U.S.-made technology and materials, the initiative could generate hundreds of well-paying jobs across construction, operations, maintenance, and engineering while fostering innovation in the data center industry and other high-energy sectors.
The projects aim to deliver abundant, reliable power to data centers within two years, ensuring continuous, scalable energy supply and uptime stability amid market fluctuations.
Brad Gray, President and Chief Financial Officer of Diversified Energy, said,&nbsp;&#8221;The market demand for the type of reliable, quickly dispatchable power that only natural gas can deliver is incredibly strong, and we&#8217;re excited about the potential of this partnership to deploy Diversified Energy-produced natural gas and coal mine methane (CMM) and pair it with Fuel Cell&#8217;s advanced industrial-scale technology to create an efficient, cost-effective, environmentally sound solution for the next generation power needs of data centers.&#8221;
Jason Few, President and CEO of FuelCell Energy, stated, &#8221;We believe the future of AI and other high-performance computing will require an abundant supply of clean, reliable, and locally generated power, ensuring that data centers can operate with maximum efficiency and sustainability.&#8221;
Karen Morgan, Managing Partner at TESIAC, stated, &#8220;We anticipate there will be multiple benefits for communities from this collaboration. Stabilizing the energy supply, while capturing methane emissions, turns an environmental challenge into an economic growth opportunity, creating steady job growth as a result of bringing the supply chain closer to the source of power and the end user.&#8221;
In January, Diversified Energy plans to acquire&nbsp;Maverick Natural Resources, an EIG portfolio company,&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/25/01/43232223/diversified-energy-to-close-1-275-billion-acquisition-of-maverick-strengthening-position-in-anadarko-and-permian-basins" rel="noreferrer noopener">for around $1.275 billion</a>.
Price Action: DEC shares closed up 0.89% at $11.28 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/44213860" target="_blank" rel="noreferrer noopener">TSMC Rides AI Wave: Sales Surge 39% In First 2 Months Of 2025 On Higher Demand</a></li>
</ul>
Photo via Shutterstock.

Contracts

Small Cap

FCEL

FuelCell Energy, Diversified Energy, TESIAC Join Forces To Meet Growing AI Power Demands

William Blair analyst Ryan Merkel upgrades W.W. Grainger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) from Market Perform to Outperform.

Upgrades

William Blair Upgrades W.W. Grainger to Outperform

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) with a Buy and maintains $10 price target.

AQST

HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target

Immunome, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1021, a ROR1-targeted ADC.
"Immunome is developing differentiated ADCs that we believe can greatly benefit cancer patients," said Bob Lechleider, M.D., Chief Medical Officer at Immunome. "The dosing of our first patient with IM-1021 advances that mission, as we work to establish safety and explore efficacy of IM-1021 in patients with high unmet need in B-cell lymphomas and solid tumors."
IM-1021 is an optimized, ROR1-targeted ADC that incorporates Immunome's proprietary TOP1 inhibitor, HC74. The Phase 1 trial is an open-label, multicenter dose escalation and expansion study designed to determine the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of IM-1021. The study is expected to include participants with advanced B-cell lymphomas and advanced solid tumors.

IMNM

Immunome Doses First Patient in Trial for New Cancer-Fighting Drug IM-1021

William Blair analyst Ryan Merkel upgrades Fastenal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) from Market Perform to Outperform.

FAST

William Blair Upgrades Fastenal to Outperform

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) with a Buy and raises the price target from $8 to $11.

CDXC

HC Wainwright & Co. Maintains Buy on ChromaDex, Raises Price Target to $11

The United States is considering a potential partnership with the Democratic Republic of Congo (DRC) to secure access to <a target="_blank" href="https://www.benzinga.com/markets/commodities" rel="noreferrer noopener">critical minerals</a>, following discussions initiated by a senior Congolese official.
According <a target="_blank" href="https://www.ft.com/content/3f638e29-4790-4a10-b5b7-a79f9ef55491" rel="noreferrer noopener">to</a> the Financial Times, the DRC proposed a minerals-for-security deal, offering valuable resources for military support to address ongoing conflict in the region, particularly with the M23 rebel group who seized control of eastern parts of the North Kivu province.
President Felix Tshisekedi recently hinted at the deal in an interview for the New York Times, while a State Department spokesperson confirmed the situation.
"The DRC is endowed with a significant share of the world's critical minerals required for advanced technologies. The United States is open to discussing partnerships in this sector that align with the Trump administration's America First agenda," they said.
The DRC has significant mineral resources, including cobalt, lithium, copper, and tantalum. It is a global leader in cobalt production, supplying over 70% of the metal's production. Cobalt is essential for electric vehicle batteries and renewable energy technologies.
Still, its status has been problematic, as declining prices forced foreign operators like the Chinese miner MMG to <a target="_blank" href="https://www.benzinga.com/news/global/25/03/44168899/mmg-pauses-cobalt-production-in-congo-as-price-hits-historic-lows" rel="noreferrer noopener">pause production</a>. Meanwhile, the government implemented a four-month export ban to stabilize the oversupplied market.
On top of illegal mining and smuggling, escalating armed conflicts are likely the main catalyst for ongoing talks with Washington. The M23 rebel group, allegedly backed by neighboring Rwanda, has seized significant territory in the eastern part of the country, threatening mineral-rich territory.
Since the conflict has also drawn in neighboring Burundi and Uganda, the situation risks escalating into a full-scale regional conflict.
While a deal with the U.S. would stabilize the region, in exchange, the U.S. would gain access to critical minerals and reduce reliance on Chinese-dominated supply chains.
China controls most of the DRC's mining sector through the state-owned MMG. Washington could seize this opportunity to reduce Beijing's influence while securing resources for its industrial needs.
Yet, a deal between Washington and Kinhasa is a tall order. The political climate in Kinshasa is volatile, and past foreign mining agreements in the DRC have faced criticism over transparency issues.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44188315/germany-could-meet-its-lithium-needs-from-domestic-sources-study-says" target="_blank" rel="noreferrer noopener">Germany Could Meet Its Lithium Needs From Domestic Sources, Study Says</a></li>
</ul>
Photo via Shutterstock

Government

Commodities

Politics

BATT

CARZ

DRIV

IDRV

KARS

DR Congo Explores Minerals-For-Security Deal With The US

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) with a Buy and maintains $19 price target.

ALMS

HC Wainwright & Co. Reiterates Buy on Alumis, Maintains $19 Price Target

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) with a Buy and maintains $8 price target.

HC Wainwright & Co. Reiterates Buy on Unity Biotechnology, Maintains $8 Price Target

The acquisition marks a significant step in NETCLASS' strategy to expand its market across Asia. It provides the Company with a new operational center in Tokyo, Japan, and signifies the Company's dedication to its long-term plan through enhancing its software development capability, improving the quality of existing products, and diversifying its customer base

NTCL

NETCLASS TECHNOLOGY Enters Japan Market Via Strategic Acquisition Of Createsolutions; Eyes Regional Growth And Innovation

Today, during TMC's 2025 Annual Meeting &amp; Transportation Technology Exhibition, <a href="https://www.globenewswire.com/Tracker?data=oIBFlhCGj2iyGabzNvH-QtyhXc01zojN8oJuOF7d4khNcCYSVMrKSahqpheVBRVrOBV8ah7WHFnXKLTQJS6ODuT6rH1mclWPco71lhbyDaDAAn69LrrIKnMFs2hsjI20yxrpHrNKmxreMvlYbcPO-oieXFvpAsat3VPHRU7V4jvkIU2qZIMVNJ00iHMDyLADb13xqQhrUWHPtd1ORaAp25AKvE6YIxr4dbbyGx9Qtc5sUtkwcYPFVC-cgVwlPNLwPpINCtaUct3ZJtImL0Or0zzr8hVBjtLYfjHaWM0Nx8R2x5wLpDul2ePtqXN2uFZYAutho7AHfx5vGat2_46S1Ae3YYgRTa2jqdqqDNZvhhq2p35254qxfc2DE211stlDK4XRRD0kWV3DWbhnNaDLEw==">Dragonfly Energy Holdings Corp.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) ("Dragonfly Energy" or the "Company"), an industry leader in energy storage and battery technology, unveiled the new Battle Born&#xAE; DualFlow Power Pack. This innovative lithium power system is designed to eliminate idle time and alleviate strain on starter batteries by providing dedicated power for hotel loads in long haul trucks. Engineered for universal compatibility, the DualFlow Power Pack installs inside the sleeper cab under the bunk without any modifications to existing systems.
The DualFlow Power Pack powers auxiliary loads while the truck is parked by removing cycles from the starter batteries and extending the lifespan while reducing unnecessary engine starts. Once the truck is back in motion, it recharges using Wakespeed&#xAE; Charge Control Technology, making use of available energy without additional fuel consumption. Designed for Heavy-Duty Trucking fleets and owner-operators with sleeper cabs, it is particularly well-suited for fleets that do not use auxiliary air conditioners. With a low price point and an ROI well under a year, the Company believes fleets can quickly recover their investment and witness significant real-world savings in fuel costs, battery replacements, and maintenance.

DFLI

Dragonfly Energy Unveils DualFlow Power Pack to Cut Truck Idle Time, Save Fuel

This is inclusive of non-recurring first-of-a-kind, Project Permian site-specific and owner costs. Provided the successful value engineering process, the project would come online no earlier than 2029.

NPWR

Net Power Now Estimates Project Permian's Total Installed Cost To Be Between $1.7B And $2.0B

Citigroup analyst Spiro Dounis upgrades Pembina Pipeline (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PPL#TSX">PPL</a>) from Neutral to Buy and announces C$63 price target.

TSX:PPL

Citigroup Upgrades Pembina Pipeline to Buy, Announces C$63 Price Target

CYTK

Cytokinetics Said Maintain Expectation For Differentiated Label & Risk Mitigation Profile For Aficamten, If Approved By FDA

<ul>
<li>ARO-C3 achieved deep and sustained reductions in alternative pathway complement activity and proteinuria.</li>
<li>Mean sustained reductions in C3 of ≥87%, AH50 of ≥76%, Wieslab AP of ≥89% through week 24.</li>
<li>Mean reduction in spot urine protein-to-creatinine ratio (UPCR) of 41% by week 24</li>
</ul>

Biotech

Health Care

General

ARWR

Arrowhead Pharmaceuticals Announced Topline Results From Part 2 Of A Phase 1/2 Study Of ARO-C3 To Reduce Liver Production Of Complement Component 3 As A Potential Therapy For Various Complement Mediated Diseases

Press Releases

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results

Comments

Legend Biotech

ニュース

パートナーシップ

ベンジンガ・グローバル